ICRF-159 enhancement of radiation response in combined modality therapies. I. Time/dose relationships for tumour response.
The combined effect of the chemotherapeutic agent ICRF-159 and irradiation were evaluated using the Lewis lung tumour (LL). At a daily dose of 25 mg/kg, ICOF given alone prevented the progressive growth of LL. Daily pretreatment also potentiated the effects of radiation (600 rad) on tumour growth, provided the pretreatment kinetics of the tumour permitted a response to radiation alone. Single acute doses of the drug failed to alter the growth of LL, and when combined with radiation failed to enhance the radiation effect. Fractionation of the drug (25 mg/kg; 4 doses at 3h intervals) before irradiation, however, results in immediate effects on tumour growth which are more than additive. The results suggest that a low dose of ICRF-159 for extended periods is more effective in enhancing radiotherapy than a high dose provided acutely.
D000818:Animals; D004334:Drug Administration Schedule; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D051379:Mice; D009374:Neoplasms, Experimental / Q000628:therapy; D010879:Piperazines / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents; D011929:Razoxane / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D010879:Piperazines; D011838:Radiation-Sensitizing Agents; D011929:Razoxane